Trump administration sets preliminary cuts to Medicare lab reimbursement rates
The American Clinical Laboratory Association warned the steep annual payment cuts threaten patient access to critical lab testing services.
STAT+ delves into whether the Trump administration may have just delivered a significant financial boon to Novo Nordisk. The outlet previously reported on the advantageous deals struck by both Eli Lilly and Novo Nordisk to lower the costs of obesity drugs for seniors under the Trump administration. According to the latest piece, Novo Nordisk may have received an additional advantage in these negotiations. Readers interested in the full story can continue their read on STAT+.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
